

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 7797

Title: Emerging role of the KRAS-PDK1 axis in pancreatic cancer

Reviewer code: 02536967

Science editor: Wen, Ling-Ling

Date sent for review: 2013-11-30 21:12

Date reviewed: 2013-12-09 04:13

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

Major critiques: none Minor critiques: Consider expanding the discussion to be more comprehensive: 1. The authors suggest miR-375 as a potential therapeutic strategy. Recently, miR-375 has been found significantly downregulated in multiple types of cancer, and suppresses core hallmarks of cancer by targeting several important oncogenes like AEG-1, YAP1, IGF1R and PDK1. Would discuss these additional targets as it relates to pancreatic cancer. 2. At AACR 2012, a study demonstrated nanoparticles delivery of a novel AKT/PDK1 inhibitor inhibits pancreatic cancer tumor growth. 3. Highly selective PDK1 inhibitors are now available and combination strategies may achieve more effective blockade of this axis.

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 7797

Title: Emerging role of the KRAS-PDK1 axis in pancreatic cancer

Reviewer code: 02566924

Science editor: Wen, Ling-Ling

Date sent for review: 2013-11-30 21:12

Date reviewed: 2013-12-24 21:35

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

1. The capitalization of some words is inconsistency, such as KRAS or PDK1. 2. Page 7, line 10: The example of NSCLC is not enough for making the conclusion that PDK1 has a specific role downstream of KRAS in pancreatic cancer. 3. There may be more references to be cited.